Despite the utility of the number of tyrosine kinase inhibitors (TKIs) that block the oncogenic signaling triggered by FLT3, primary and secondary acquired resistance to FLT3 inhibitors, such as quizartinib, remains a challenge in FLT3-ITD AML treatment (115). This evidence concerns the gene FLT3 and acute myeloid leukemia.